For the quarter ending 2026-03-31, AORT had -$9,144K decrease in cash & cash equivalents over the period. -$6,849K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 1,417 | 2,426 | 6,502 | 840 |
| Depreciation and amortization | 6,340 | 5,757 | 5,717 | 10,984 |
| Non-cash compensation | 8,414 | 4,083 | 6,135 | 14,167 |
| Non-cash lease expense | 1,297 | 1,346 | 1,314 | 2,510 |
| Write-down of inventories and deferred preservation costs | 1,062 | 1,121 | 1,400 | 2,379 |
| Non-cash interest expense | - | 1,705 | - | - |
| Deferred income taxes | -524 | 1,521 | -1,253 | -231 |
| Change in fair value of contingent consideration | 1,740 | 5,310 | 2,600 | -210 |
| Endospan fair value adjustments | - | -2,337 | - | - |
| Losses on inducement/extinguishment of debt | - | 0 | 0 | -2,664 |
| Gain from sale of non-financial assets | - | 3,500 | 3,500 | - |
| Other | 537 | -94 | 108 | -7,423 |
| Receivables | 2,760 | 6,345 | -8,736 | 9,660 |
| Inventories and deferred preservation costs | 6,379 | 3,714 | 6,042 | 5,521 |
| Prepaid expenses and other assets | 1,286 | -2,905 | -1,512 | 6,215 |
| Accounts payable, accrued expenses, and other liabilities | -8,704 | 9,376 | -967 | -6,226 |
| Net cash flows provided by (used in) operating activities | 1,154 | 19,560 | 22,262 | -1,942 |
| Capital expenditures | 8,003 | 27,507 | 4,609 | 6,925 |
| Payments under endospan agreements | - | 8,000 | 0 | - |
| Payments related to sale of non-financial assets | 1,500 | - | - | - |
| Proceeds from sale of non-financial assets, net | - | 5,000 | - | - |
| Payments for endospan agreements | 1,000 | - | - | - |
| Net cash flows used in investing activities | -10,503 | -30,507 | -4,609 | -6,925 |
| Proceeds from issuance of long-term debt | - | 0 | 0 | 0 |
| Proceeds from revolving credit facility | - | 0 | 0 | 0 |
| Repayment of debt | 0 | 3 | 73 | 134 |
| Proceeds from exercise of stock options and issuance of common stock | 1,250 | 3,461 | 5,154 | 4,459 |
| Payment of debt issuance costs | - | 0 | 1,750 | 0 |
| Proceeds from financing insurance premiums | - | 0 | 0 | 3,117 |
| Principal payments on short-term notes payable | 577 | 855 | 841 | 554 |
| Redemption and repurchase of stock to cover tax withholdings | - | 0 | - | - |
| Other | -210 | -173 | -173 | -353 |
| Net cash flows provided by financing activities | 463 | 2,430 | 2,317 | 6,535 |
| Effect of exchange rate changes on cash and cash equivalents | -258 | -1 | -20 | 2,345 |
| Decrease in cash and cash equivalents | -9,144 | -8,518 | 19,950 | 13 |
| Cash and cash equivalents beginning of period | 64,908 | 73,426 | 53,463 | - |
| Cash and cash equivalents end of period | 55,764 | 64,908 | 73,426 | - |
ARTIVION, INC. (AORT)
ARTIVION, INC. (AORT)